Nyla Hashim
Family · Santa Fe, NMNPI 1659914851
Payments from drug & device makers
Across 64 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$351
- Takeda Pharmaceuticals U.S.A., Inc.$271
- GSK$177
- Incyte Corporation$135
- Regeneron Healthcare Solutions, Inc.$82
- Sanofi$77
- plus $232 from 8 others
What the payments were for
- Food & beverage$1,26996%
- Education$554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $271 |
| GSK | 8 | $177 |
| Incyte Corporation | 7 | $135 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| Sanofi | 3 | $77 |
| Genentech USA, Inc. | 3 | $70 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Grifols USA, LLC | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| AbbVie | 1 | $16 |
| Merck | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $16 |
| CSL Behring | 1 | $15 |
How this compares
$1,324 in reported general payments places this provider in the 80th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,386 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,085 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,658 |
| Epinephrine | 11 | $3,331 |
| Azelastine Hcl | 70 | $2,020 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,695 |
| Ipratropium Bromide | 37 | $1,253 |
| Fluticasone Propionate | 23 | $479 |
| Montelukast Sodium | 22 | $164 |
| Prednisone | 17 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $177 | $27,47044 claims |
| AstraZenecaSymbicort | $351 | $6,65823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,080 family providers in New Mexico.
Other family in Santa Fe
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
- Katie BoylanRio Rancho$11K
- Charles GallegosAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.